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Therapy in Type 1 Diabetes Mellitus
ABStRAct
type 1 diabetes mellitus is the result of the autoimmune response against 
pancreatic β-cell(s). At the time of clinical diagnosis near 70% of β-cell mass is 
been destroyed as a consequence of the auto-destruction that begins months 
or even years before the clinical diagnosis. Although marked reduction of 
chronic complications was seen after development and progression of insulin 
therapy over the years for type 1 diabetic population, associated risks of chro-
nic end-organ damage and hypoglycemia still remain. Besides tight glucose 
control, β-cell mass preservation and/or increase are known to be other im-
portant targets in management of type 1 diabetes as long as it reduces chro-
nic microvascular complications in the eyes, kidneys and nerves. Moreover, 
the larger the β-cell mass, the lower the incidence of hypoglycemic events. in 
this article, we discuss some insights about β-cell regeneration, the importan-
ce of regulation of the autoimmune process and what is being employed in 
human type 1 diabetes in regard to stem cell repertoire to promote regenera-
tion and/or preservation of β-cell mass. (Arq Bras Endocrinol Metab 2008; 
52/2:407-415)
Keywords: diabetes mellitus; β-cell; regeneration/preservation; immune in-
tervention; stem cell; transplant
RESuMO
O potencial das células-tronco no tratamento do Diabetes Melito 
tipo 1.
o diabetes melito tipo 1 (dM1) é o resultado de uma resposta auto-imune 
contra as células-beta pancreáticas. Por ocasião do diagnóstico clínico do 
dM1, aproximadamente 70% da massa de células-beta foram destruídas 
como conseqüência de uma autodestruição que se iniciou há anos ou meses 
antes dos primeiros sinais da doença. embora a redução acentuada das com-
plicações crônicas na população com dM1 foi observada após o desenvolvi-
mento e evolução da insulinoterapia, os riscos associados às lesões dos 
órgãos-alvo e hipoglicemia persistem. Além do controle intensivo da glice-
mia, a preservação e/ou o aumento da massa de células-beta são reconheci-
dos como alvos importantes no tratamento do dM1. isto vem associado à 
redução das complicações crônicas microvasculares na retina, rins e nervos 
e a menor incidência de eventos hipoglicêmicos. neste artigo, discutimos 
alguns aspectos da regeneração das células-beta pancreáticas, a importância 
da regulação do processo auto-imune e o que está sendo empregado no dM1 
humano com relação ao repertório das células-tronco nesse sentido. (Arq 
Bras Endocrinol Metab 2008;52/2:407-415)
Descritores: diabetes tipo 1; células-beta; regeneração/preservação; imu-
noterapia; células-tronco; transplante
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Studies of pathologic anatomy of pancreas from pa-
tients soon after the diagnosis of T1DM suggest that 
approximately 10-20% of normal β-cell mass still re-
mains. Interestingly, functional analysis of newly diag-
nosed patients indicates that average total insulin 
secretion in response to a mixed meal is around 50% of 
that seen in matched non-diabetic population (8). 
GlucOSE cONtROl iS NOt thE uNiQuE 
fOcuS iN thE MANAGEMENt Of t1DM
Blood glucose control is the most important target in 
the management of diabetes mellitus. Since patients 
with T1DM depend on daily exogenous insulin admin-
istration for survival, the best-established goal is tight 
control of glucose levels achieved by multiple daily in-
jections or continuous subcutaneous infusion of insu-
lin, ie, intensive insulin therapy. This treatment is 
known to reduce the risk of microvascular complica-
tions by 35% to 90% when compared with convention-
al therapy with only 1 to 2 injections per day (9), but is 
not the only way to prevent chronic complications in 
individuals with T1DM. Moreover, even in the most 
strictly-controlled patients, associated risks of chronic 
end-organ damage and hypoglycemia still remain. 
Subgroup analysis of the Diabetes Control and 
Complication Trial (DCCT) has showed an important 
aspect related to long term complications of the dis-
ease, ie, patients with higher serum levels of C-peptide 
iNtRODuctiON
Type 1 diabetes mellitus (T1DM) results from a cell-mediated autoimmune attack against pancre-
atic β-cells. The autoimmune response may begin years 
before the clinical diagnosis. Since more than 70-80% 
of β-cell mass has been destroyed at the time of disease 
onset, the autoimmune process is markedly advanced 
when hyperglycemia appears (1,2) (Figure 1). 
The pancreatic microenvironment is considered to 
be the primary location of autoreactive T-cells in 
T1DM. However, in animal models the presence of au-
toreactive diabetogenic T-cells have also been detected 
in the spleen (3) and bone marrow (4) of NOD mice 
and this presence can also be detected long before cli-
nical onset of the disease. 
The rate of β-cell destruction in the preclinical phase 
is rapid in children associated with much less β-cell mass 
at the time of diagnosis; in contrast, in adults the rate 
of auto-destruction is slower, with larger β-cell mass at 
diagnosis (5). Another predictor of the poor amount of 
viable β-cell mass at diagnosis is the presence of high-risk 
major histocompatibility complex, such as DRB1*03-
DQB1*0201/DRB1*04-DQB1*0302 (6). Moreover, 
some investigators argue in favor of sex differences in 
β-cell mass at clinical presentation of T1DM, being 
β-cell destruction more extensive in post-pubertal fe-
males than males. Such difference was not observed in 
pubertal or pre-pubertal individuals (7). 
Figure 1 Schematic rate of β-cell destruction function of different phases of type 1 diabetes mellitus – 
preclinical phase, recent diagnosis and longterm disease.
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after diagnosis with sustained levels over the years suf-
fered less microvascular complications and less hypo-
glycemic events than those patients with low or 
undetected levels of C-peptide. In conclusion, β-cell 
preservation is another important target in the man-
agement of T1DM and its related complications (10). 
In non-diabetic population β-cell mass changes in 
response to different physiological and pathologic pro-
cess during adult life such as pregnancy, abdominal 
obesity and states of insulin resistance (11,12). This 
phenomenon of β-cell adaptation in face of innume-
rous challenges experienced after birth is resultant of 
neogenesis, proliferation or apoptosis (13). 
Plasticity and spontaneous regeneration capacity of 
β-cell mass can be demonstrated in animal models or in 
humans. In normal animals or in rat diabetic models, 
chronic high-dose glucose infusion protocols showed 
increase in cell mass, in cell function, in neogenesis and 
in cell replication indices (14-17). In another study, 
young near-totally-pancreatectomized rats presented a 
spontaneous eight-week-regeneration of 27% of pan-
creas weight and 42% of the endocrine pancreas (18). 
In contrast, a recent study in humans has failed to evi-
dence β-cell proliferation after partial pancreatectomy 
(19). However, an impressive Japanese case report 
showed more insights about β-cell regeneration in hu-
mans: a 39-year-old type 1 diabetic patient submitted 
to simultaneous pancreas-kidney transplantation was 
referred to treat an abdominal incision herniation 2 
years after the initial procedure. A regimen with tacroli-
mus, prednisolone and micophenolate was used since 
transplantation and good glycemic control was achieved 
without exogenous insulin. At the time of the correc-
tive surgery, native pancreas biopsy showed that the 
percent of β-cells was 4 fold greater than that observed 
in long term type 1 diabetic patients conventionally 
treated with insulin (20). 
iNSiGhtS ABOut β-cEll REGENERAtiON
In light of recent discoveries demonstrating the regen-
erative potential of the pancreas, many researches have 
been made with the aim of identifying which cell or 
cells could be the precursors of adult cells. The clonal 
isolation of putative pancreatic precursors has been an 
elusive objective of researchers who look for a more 
complete knowledge of β-cell physiology and for new 
replacement strategies for T1DM. 
The presence of a group of characteristics is neces-
sary to indicate if a progenitor cell is able to differentia-
te into pancreatic cells. It includes: insulin staining, 
presence of activated specific cell genes, progressive in-
sulin secretory pattern in vitro in response to greater 
glucose concentration of the medium, and reversal or 
prevention of hyperglycemia in animal models of 
T1DM after progenitor cell administration. 
The great majority of studies of cell precursors were 
developed in animal models and each protocol has its 
own pros and cons (21,22). Several candidate precur-
sors of adult cells were studied: 
adult pancreatic cell itself (23-25);•	
pancreas-derived multipotent progenitor (26);•	
pancreatic duct cells (27);•	
bone marrow-derived mesenchymal stem cells •	
(28-31);
bone marrow-derived hematopoietic stem cells •	
(32-35);
hepatic oval cells (36-38); •	
spleenocytes (39,40);•	
umbilical cord blood cells (21,42,43); •	
embryonic stem cells (44,45).•	
As mentioned above, a variety of tissues harbors 
progenitor or stem cells. The pancreas is an obvious 
source tissue and a number of studies have suggested 
the existence of stem cells within the pancreas. What is 
not exactly known is if pancreas-derived progenitor 
cells are primarily inside pancreatic parenchyma since 
early pancreas embryogenesis, or if these cells have 
other sources (bone marrow or duct cells, for example) 
and then migrated to the pancreatic tissue. Another hy-
pothesis is that pancreatic duct cells differentiate into 
pancreatic β-cells and it was widely studied in animal 
models (27). Recently, Yatoh and colleagues have sho-
wed that pancreatic duct cells purified from islet-deple-
ted human tissue can differentiate in vitro to insulin 
producing cells (46). 
Bone marrow is another important probable source 
of adult β-cells and among cell population presented in 
bone marrow mesenchymal stem cells have more noto-
rious impact in this regard. In 2004, Chen and col-
leagues (29) induced in vitro β-cell differentiation 
under appropriate conditions. These cells evidenced 
glucose-dependent insulin secretion in vitro and, when 
transplanted into streptozotocin-induced diabetic rats, 
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could down-regulate blood glucose levels. In 2006, 
Lee and colleagues (30) showed a decrease in glucose 
levels, an increase in β-cell mass and pancreatic islets in 
NOD/scid mice that received intracardiac human mes-
enchymal stem cells. Additionally, these infused cells 
also promoted adjuvant effects in the kidneys by de-
creasing mesangial thickening and by reducing mac-
rophage infiltration. Recently, Urbán and colleagues 
(31) have showed that mesenchymal stem cells, aside of 
promoving β-cell regeneration in streptozotocin-in-
duced diabetic mice, inhibit T-cell-mediated immune 
response against newly-formed β-cells in which are able 
to survive in this altered imunological milieu. 
A less promising scenario is seen in studies of he-
matopoietic stem cells. As bone marrow hematopoietic 
stem cells were able to differentiate into hepatocytes 
and ultimately regenerate liver in animal models 
(32,33), attempts were made to evaluate their possible 
role in β-cell regeneration. However, Kang and col-
leagues (34) showed that hematopoietic stem cell trans-
plantation prevents diabetes in NOD mice but does not 
contribute to significant islet cell regeneration once the 
disease is established. Moreover, in 2007 Butler and 
colleagues (35) evaluated 31 human pancreata obtained 
at autopsy from hematopoietic stem cell transplant re-
cipients who had received their transplant from a donor 
of the opposite sex. In this study, in spite of observing 
donor-derived cells in the non-endocrine pancreata, 
they did not demonstrate the presence of donor-de-
rived β-cells. 
Umbilical cord blood (UCB) is an important source 
of stem cells and regulatory T cells, with potential to 
promote in vivo β-cell regeneration. Moreover, much 
attention is kept on their immunomodulatory effects in 
autoimmune diseases. In a xenogenic model of stem 
cell transplantation, human mononuclear UCB cells 
were able to reduce blood glucose levels and increase 
survival in mouse models of type 1 and type 2 diabetes 
mellitus (41). In other animal model of diabetes (type 
2), UCB cell infusion also improved renal abnormali-
ties and neuropathy caused by diabetes, suggesting a 
regenerative action in renal parenchyma and nerves 
(42,43). These dual effects – regenerative and immu-
nomodulatory – are of great importance in the regard 
of autoimmune T1DM and as previously seen, this ca-
pacity is also seen in studies of mesenchymal stem cells 
(31,47,48). 
Embryonic stem cells (ESC) are pluripotent cell 
lines derived from the inner cell mass of blastocyst-
stage embryos and their differentiation in culture may 
reproduce characteristics of early embryonic develop-
ment. For this reason, ESC are considered as having 
unlimited potential in generating differentiated adult 
cells, including pancreatic β-cells. Beginning in 2000, it 
has been reported by many research groups that ESC 
can differentiate into β-cells in vitro. In 2001, Assady 
and colleagues (49), using human ESC, evidenced the 
spontaneous in vitro differentiation of cells with spe-
cific characteristics of β-cell in both adherent and sus-
pension culture conditions. After embryoid body 
development, 3% of all cells positively stained for insu-
lin at a maximal density evidenced markers of β-cell 
identity, such as glucose transporter protein GLUT2 
and glucokinase genes, Pdx-1/Ipf-1 and neurogenin-3 
transcription factors. Functional analyses evidenced se-
cretion of insulin into the medium in response to dif-
ferent glucose concentrations. 
Stimulated by several recent reports claiming the 
generation of insulin-producing cells from ESC, Hans-
son et al. (50) investigated the properties of these insu-
lin-containing progenitors. In this study they found 
that although differentiated cells containing immuno-
reactive insulin has been isolated, they did not contain 
proinsulin-derived C-peptide. Furthermore, in spite of 
variable insulin release from these cells upon glucose 
addition, C-peptide release was never detected. Thus, 
the authors suggest that C-peptide biosynthesis and se-
cretion should be demonstrated to claim insulin pro-
duction from embryonic stem cell progeny. 
Another point related to ESC is the ethical issues 
surrounding stem cell therapy. Discussions are complex 
and involve not only technical aspects but also philoso-
phical questions related to the beginning of individual 
life (51). Other ways have been developed to solve tho-
se ethical problems. Recently, Byrne and colleagues 
(52) have used a modified somatic cell nuclear transfer 
approach to produce rhesus macaque blastocysts from 
adult skin fibroblasts, and successfully isolated two ESC 
lines from these embryos. DNA analysis confirmed that 
nuclear DNA was identical to donor somatic cells and 
that mitochondrial DNA originated from oocytes. 
In autoimmune diseases the potential role of stem 
cell therapy is somewhat different from pure degenera-
tive diseases. For example, in cases of myocardial infarc-
tion, it seems obvious to use stem cells to regenerate 
necrotic tissue. However, in T1DM the regenerative 
process of β-cell mass using stem cell therapy should be 
associated with safe strategies of immunomodulation to 
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block autoimmunity against newly differentiated β-cells 
formed by stem cell transplantation (22,53). In Figure 
2, we summarize potential use of stem cell therapy as-
sociated with immunomodulatory approaches in indi-
viduals with T1DM in different clinical settings. It is 
important to note that in recent-onset or even in pre-
clinical phase, immunomodulatory strategies can be 
done as the unique therapeutic approach since larger 
residual β-cell mass is still functioning and able to be 
preserved. Moreover, immunomodulation secondarily 
facilitates endogenous mechanisms of β-cell prolifera-
tion once the pathologic process of β-cell destruction is 
blocked. 
StuDiES iNvOlviNG StEM cEll 
thERApy iN huMAN t1DM
Autologous nonmyeloablative hematopoietic 
stem cell transplantation
In 2003, our research group started an original study 
of autologous nonmyeloablative hematopoietic stem 
cell transplantation in patients with newly diagnosed 
T1DM. The objective of the treatment is to stop auto-
immune destruction of β-cells with high-dose immu-
nosuppressive drugs (cyclophosphamide and rabbit 
antithymocyte globulin) and to “reset” the deleterious 
immunologic system with a reconstituted one origi-
nated from autologous hematopoietic stem cells (54). 
The rational is to preserve residual β-cell mass and fa-
cilitate endogenous mechanisms of β-cell regeneration. 
As shown above, hematopoietic stem cells do not have 
the capacity to differentiate into β-cells. So, in this case, 
hematopoietic stem cells are used solely to regenerate a 
“renewed” autoimmune system without previous im-
munologic memory against pancreatic antigens. 
The exact mechanism operating in this protocol is 
unclear, but it may shift the balance between destructi-
ve immunity and tolerance through yet undefined me-
chanisms such as clonal exhaustion, suppressor cells, 
immune indifference, cytokine alterations, changes in 
T- or β-cell clonality or changes in immunodominant 
autoantigens (55). 
The first patient enrolled presented discouraging 
response. His insulin requirements increased progressi-
vely until 12 months following transplantation (when 
Figure 2 Potential therapeutic use of stem cell therapy for patients with type 1 diabetes mellitus in three 
distinct clinical settings: newly-diagnosed type 1 diabetes, pre-clinical and long-term type 1 diabetes.
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he abandoned follow-up) reaching the dose 250% hi-
gher than his initial requirement. His hemoglobin A1c 
was 11.1% at 12 months and his C-peptide concentra-
tions did not increase. The possible causes for his poor 
clinical response are the very low β-cell reserve predic-
ted by the previous diagnosis of diabetic ketoacidosis 
that was further jeopardized by β-cell apoptotic effect 
of glucocorticoids used in the conditioning regimen to 
prevent possible rabbit antithymocyte globulin reac-
tions. In face of this, we decided not to use glucocorti-
coids in the conditioning regimen in the following 
patients and did not include those with previous diabe-
tic ketoacidosis. 
During a mean follow-up of 23.8 months (range 
between 1 to 45 months) in November 2007, all the 
subsequent 18 patients became insulin-free, most of 
them shortly after starting high dose immunosuppres-
sion and even before stem cell infusion. Of these 18 
patients, 4 resumed insulin use after transient periods 
free from insulin ranging from 7 to 12 months. The 
other 14 patients are continuously without insulin use 
since insulin suspension: 3 patients for at least 3 years, 
4 patients for at least 2 years, 3 patients for at least 1 
year and 3 patients for at least 3 months (Figure 3). 
The 19th patient was just a few days free from insulin. 
There was a statistically significant reduction of mean 
hemoglobin A1c concentrations after transplantation. 
All but 2 patients (the 1st and the 11th) presented all me-
asurements below 7% (upper limit of good glucose con-
trol) during follow-up. As noted above, soon after 
inclusion, the 1st patient did not achieve good glucose 
control. The 11th patient presented A1c levels < 7% until 
12 months after transplantation when insulin use was 
restarted and hemoglobin A1c began to increase. 
With respect to time course of β-cell function of 
the first 14 patients who had C-peptide levels analyzed, 
the majority (n=11) presented increased values in com-
parison with pretreatment levels, indicating preserva-
tion and even improvement β-cell function. Analyzing 
C-peptide levels during a stimulus with mixed meal to-
lerance test, there was a statistically significant increase 
in mean area under the curve 6 months after transplan-
tation and this increase was maintained until 24 mon-
ths after stem cell transplantation. 
Figure 3 Time free from insulin of the first 10 patients with type 1 diabetes enrolled for autologous nomyeloab-
lative hematopoietic stem cell transplantation.
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In face of the good metabolic results presented, the 
adverse effects were acceptable. With respect to acute 
complications, most patients had febrile neutropenia, 
nausea, vomiting, alopecia due to the drugs used in the 
study protocol, especially immunosuppressive agents. 
Bilateral pneumonia of unidentified etiology that re-
quired supplementary oxygen therapy and responded 
completely to broad-spectrum antibiotics occurred in 
patient 2 and was the only severe acute complication of 
ASCT. During long-term follow-up, patient 2 presen-
ted Graves disease identified 3.5 years after transplanta-
tion, patient 3 developed autoimmune hypothyroidism 
and transient renal dysfunction associated with rhab-
domyolysis, a complication that was successfully treated 
with levothyroxine presented mild transient hypergo-
nadotropic hypogonadism 12 months after transplanta-
tion. These late onset endocrine dysfunctions presented 
by these 3 patients can be related to the transplant pro-
cedure itself or by autoimmune polyendocrine syndro-
me frequently associated with T1DM. There was no 
mortality. 
In July 2007 we developed a similar study of nomye-
loablative autologous hematopoietic stem cell transplan-
tation solely in newly diagnosed individuals with T1DM 
who presented previous diabetic ketoacidosis. By No-
vember 2007 only one patient had been enrolled in the 
study, insulin independence was not achieved, but insu-
lin doses decreased by less than 50% of the initial requi-
rements. 
Autologous umbilical cord blood 
transfusion
In 2007, Haller and colleagues presented preliminary 
data on the metabolic effects of autologous umbilical 
cord blood transfusion in 7 diabetic children with re-
cent-onset T1DM (56). As seen above, the rational of 
the use of this source of stem cells is to promote both 
immunoregulation and β-cell regeneration. 
Mean age of the enrolled patients was 4.4 years, 
mean time since diagnosis was 9.6 months and mean 
daily insulin requirements was 0.45 IU/kg/day. Du-
ring a follow-up of only 6 months, patients who recei-
ved umbilical cord blood transfusion presented lower 
hemoglobin A1c levels associated with lower insulin re-
quirements when compared to children who received 
insulin therapy alone. However, spite of the short 
follow-up, C-peptide levels have declined and no pa-
tient became insulin-free.
Bone marrow mononuclear cells
Cell therapy groups in Argentina and Peru have been 
using unfractionated bone marrow mononuclear cells 
via splenic artery to treat long standing type 1 and type 
2 diabetic patients. The proposed mechanism is the an-
giogenic activity of bone marrow cells in the pancreas 
improving β-cell function. In patients with T1DM, in-
tra-arterial infusion of bone marrow cells in the pan-
creas showed no metabolic improvement after 1 year of 
follow-up as expressed by no reductions in hemoglobin 
A1c and in daily insulin requirements and by no in-
crease in C-peptide levels (57). Moreover, these results 
are expected to be replicated in larger controlled trials 
and be fully published in peer-reviewed journals.
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